These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22274661)

  • 1. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity.
    Van Summeren A; Renes J; van Delft JH; Kleinjans JC; Mariman EC
    Toxicol In Vitro; 2012 Apr; 26(3):373-85. PubMed ID: 22274661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells.
    Van Summeren A; Renes J; Bouwman FG; Noben JP; van Delft JH; Kleinjans JC; Mariman EC
    Toxicol Sci; 2011 Mar; 120(1):109-22. PubMed ID: 21163907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of potential hepatotoxicity induced by drugs.
    Gómez-Lechón MJ; Lahoz A; Gombau L; Castell JV; Donato MT
    Curr Pharm Des; 2010 Jun; 16(17):1963-77. PubMed ID: 20236064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high content screening assay to predict human drug-induced liver injury during drug discovery.
    Persson M; Løye AF; Mow T; Hornberg JJ
    J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project.
    Gómez-Lechón MJ; Tolosa L; Castell JV; Donato MT
    Toxicol In Vitro; 2010 Oct; 24(7):1879-89. PubMed ID: 20656008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.
    Weaver RJ; Betts C; Blomme EAG; Gerets HHJ; Gjervig Jensen K; Hewitt PG; Juhila S; Labbe G; Liguori MJ; Mesens N; Ogese MO; Persson M; Snoeys J; Stevens JL; Walker T; Park BK
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):767-782. PubMed ID: 28604124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein biomarkers for in vitro testing of toxicology.
    Schrattenholz A; Šoškić V; Schöpf R; Poznanović S; Klemm-Manns M; Groebe K
    Mutat Res; 2012 Aug; 746(2):113-23. PubMed ID: 22405942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development.
    Blomme EA; Yang Y; Waring JF
    Toxicol Lett; 2009 Apr; 186(1):22-31. PubMed ID: 18996174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity.
    Zhang A; Sun H; Wang P; Han Y; Wang X
    Pharmazie; 2012 Feb; 67(2):99-105. PubMed ID: 22512077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of hepatocytes to investigate drug toxicity.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Methods Mol Biol; 2010; 640():389-415. PubMed ID: 20645064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse outcome pathway development from protein alkylation to liver fibrosis.
    Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
    Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are zebrafish larvae suitable for assessing the hepatotoxicity potential of drug candidates?
    Mesens N; Crawford AD; Menke A; Hung PD; Van Goethem F; Nuyts R; Hansen E; Wolterbeek A; Van Gompel J; De Witte P; Esguerra CV
    J Appl Toxicol; 2015 Sep; 35(9):1017-29. PubMed ID: 25663337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of new technologies to characterization and prediction of adverse effects.
    Rouquié D; Heneweer M; Botham J; Ketelslegers H; Markell L; Pfister T; Steiling W; Strauss V; Hennes C
    Crit Rev Toxicol; 2015 Feb; 45(2):172-83. PubMed ID: 25615431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlight report: towards the replacement of in vivo repeated dose systemic toxicity testing.
    Hengstler JG; Marchan R; Leist M
    Arch Toxicol; 2012 Jan; 86(1):13-5. PubMed ID: 22187068
    [No Abstract]   [Full Text] [Related]  

  • 17. ECVAM and new technologies for toxicity testing.
    Bouvier d'Yvoire M; Bremer S; Casati S; Ceridono M; Coecke S; Corvi R; Eskes C; Gribaldo L; Griesinger C; Knaut H; Linge JP; Roi A; Zuang V
    Adv Exp Med Biol; 2012; 745():154-80. PubMed ID: 22437818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA-approved drug labeling for the study of drug-induced liver injury.
    Chen M; Vijay V; Shi Q; Liu Z; Fang H; Tong W
    Drug Discov Today; 2011 Aug; 16(15-16):697-703. PubMed ID: 21624500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
    Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity.
    He JH; Guo SY; Zhu F; Zhu JJ; Chen YX; Huang CJ; Gao JM; Dong QX; Xuan YX; Li CQ
    J Pharmacol Toxicol Methods; 2013; 67(1):25-32. PubMed ID: 23128142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.